New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.

Lymphocyte-specific protein tyrosine kinase (Lck), a non-receptor Src family kinase, has a vital role in various cellular processes such as cell cycle control, cell adhesion, motility, proliferation, and differentiation. Lck is reported as a key factor regulating the functions of T-cell including the initiation of TCR signalling, T-cell development, in addition to T-cell homeostasis. Alteration in expression and activity of Lck results in numerous disorders such as cancer, asthma, diabetes, rheumatoid arthritis, atherosclerosis, and neuronal diseases. Accordingly, Lck has emerged as a novel target against different diseases. Herein, we amass the research efforts in literature and pharmaceutical patents during the last decade to develop new Lck inhibitors. Additionally, structure-activity relationship studies (SAR) and docking models of these new inhibitors within the active site of Lck were demonstrated offering deep insights into their different binding modes in a step towards the identification of more potent, selective, and safe Lck inhibitors.

Introduction

Lymphocyte-specific protein tyrosine kinase (Lck), a 56 KDa protein, is a member of the Src family of non-receptor protein kinases. Lck is involved in the phosphorylation process of a number of intracellular signalling molecules such as IL-2-inducible T-cell kinase (ITK), protein kinase C, Phosphoinositide 3-kinase (PI3K), and Zeta-chain-associated protein kinase 70 (ZAP-70). Accordingly, it regulates numerous cellular processes including cell cycle control, cell adhesion, motility, proliferation, and differentiation. The function of Lck has been extensively studied and various reports revealed different mechanistic insights into the regulation of its activity including its major role as a key activator of T cells via T cell antigen receptors (TCR) signalling. In addition to T cells, Lck is expressed in natural killer (NK) cells, NK T cells, CD5+ B-1 B cells, germinal centre and to a lesser extent in mantle zone B cells, aryl hydrocarbon receptor-activated primary human B cells, and brain including the hippocampus, cerebellum and retina. In addition to leukaemia, Lck expression was also detected in a number of solid cancers including colon cancer, lung carcinoma, and breast cancer, which led to the hypothesis that Lck may also have cancer promoting functions and hence may act as a potential therapeutic target for solid cancers.

Accordingly, Lck inhibitors were found to be promising not only for the treatment of leukaemia but also in various solid cancers. In this review, we focus on presenting the newly discovered Lck inhibitors during the last decade, discussing their structure-activity relationship (SAR), in addition to performing docking simulation models of the most promising candidates into the binding site(s) of Lck in an attempt to get insights for further investigations towards more selective, potent and safe Lck inhibitors.

Lck (structure, regulation, and physiological roles)

The strcuture of Lck has the typical backbone found in all members of the Src kinase family (Figure 1); an N-terminal site (SH4 domain), SH3 and SH2 domains, a catalytic domain at the carboxy terminal (SH1 domain), and a short C-terminal tail. The C-terminal lobe contains the activation loop (alpha-helix) which forms the phosphorylation site. Both SH2 and SH3 domains are folded to be involved in protein-protein interactions responsible for the regulation of Lck activity and signal transmission; while the main function of SH2 domain is to regulate interactions with phosphotyrosine containing elements, the SH3 domain regulates interactions with proline rich elements. The SH4 domain contains a glycine and two cysteine residues, which are myristoylated and palmitoylated, respectively, to target Lck to the plasma membrane.

Figure 1.

(A) Structure of Lck kinase domains; (B) Schematic structure of Lck: SH4, unique region (UR), SH3, SH2, SH2-kinase domain linker region (LR), kinase domain, and the C-terminal negative regulatory tail (NR), Reprinted from Ref.; (C) Lck conformations and regulation of Lck activation, Reprinted from Ref..

The regulation of Lck activity occurs via phosphorylation/dephosphorylation of crucial tyrosine residues, and by some conformational changes; Phosphorylation of Tyr505 residue by the C-terminal Src kinase (Csk) leads to Lck closure through an intramolecular interaction with the SH2 domain. The closed conformation of Lck is further stabilised by the interaction between the SH3 domain and a proline-reach region located in the SH2-kinase domain linker. On the other side, Lck opening depends on dephosphorylation of Tyr505 catalysed by the protein tyrosine phosphatase CD45. The open conformation of Lck auto- and transphosphorylates Tyr394 residue located in the activation loop within the catalytic domain resulting in Lck activation. In addition to Tyr505 and Tyr394, there are other amino acid residues regulate Lck activity; a recent study by Courtney et al. on a phosphomimetic Lck mutant found that phosphorylation of Tyr192 located in the SH2 domain may restrict the interaction between Lck and CD45, leading to hyperphosphorylation of Tyr505 and accordingly in Lck inactivation. Another study proposed that the phosphorylation of this site is Zap-70-dependent, in addition, Tyr192 residue was found to be a part of an inhibitory feedback loop, which controls the regulation of the amount of active Lck and the strength/duration of TCR signalling. Moreover, Lck activity was found to be also regulated by phosphorylation of Ser59 (another feedback circuit required for the regulation of TCR signalling). Accordingly, a number of biochemical modifications, conformational dynamics, and signalling circuits were found to regulate the activity of Lck.

At physiological level, Lck is a key factor for development of T cells in the thymus and for the function of mature T cells. It also has a major role in the activation of TCR linked signal transduction pathways (Figure 2). Plus, Lck is involved in regulation of neurite outgrowth since it plays an important role in maintaining long-term synaptic plasticity in neurons in addition to other roles related to spatial learning and memory,. As mentioned earlier, Lck is also expressed in NK T cells, NK cells, and B cells. Although the function of Lck in B-cell remains unclear, Lck was suggested to regulate B Cell Receptor Signalling (BCR) signalling,.

Figure 2.

The pathway of Lck signalling. Reprinted from Ref. .

Lck-related diseases

The human genome contains more than 500 protein kinases transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Several kinases were found to be associated with different human disorders including cancer initiation and progression. Also, the recent medicinal chemistry research targeting development of small molecule kinase inhibitors for the treatment of various diseases including cancer has been proven to be a successful strategy. Among these cancer-related kinases, Lck was reported to be the promotor of BCR signals in chronic lymphocytic leukaemia (CLL) via catalysis of the proximal phosphorylation of CD79a and the induction of distal signalling events involving phosphorylation of Syk, activation of MAPK, NF-kB, ERK, and PI3K/Akt signalling pathways that are responsible for CLL cell survival following BCR cross-linking. The treatment of CLL cells with Lck inhibitors suppressed BCR dependent cell survival leading to apoptosis suggesting the potential role of Lck inhibitors in the treatment of CLL. Lck was also found to be overexpressed and hyperactivated in patients with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL),. Low levels of Lck were also detected in thymoma and suggested to be responsible of the abnormal proliferation of immature thymocytes causing thymic tumorigenesis. Co-expression of Lck-Fyn has been reported in the development of thymomas. Other studies showed that Lck functions as a therapeutic target in acute myeloid leukaemia (AML). A recent study showed that Lck was expressed at a high level in primary central nervous system lymphoma (PCNSL) patients. Lck expression was also detected in cholangiocarcinoma,, breast cancer,,,, colon cancer,,,, and lung carcinoma,,. It was also found that Lck seems to play a role in cancer stem cells (CSC) in endometrioid cancer models and cisplatin resistance of glioma cancer stem cells,. An additional function of Lck in glioma cells has been recently described. Moreover, Lck overexpression was reported in several small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines and lung cancer specimens from patients.

The success of small molecule kinase inhibitors in the treatment of cancer, coupled with a greater understanding of inflammatory signalling cascades, has led to kinase inhibitors coming to the fore in the pursuit for new anti-inflammatory agents for the treatment of inflammatory and immune-mediated diseases. Non-receptor tyrosine kinases of the Jak, Src, Syk, and Btk families play major roles in various inflammatory and immune-mediated disorders. Lck was found to be a key player in the early allergic immune response. Antigen activation of TCR results in the activation of Lck and further downstream signalling, resulting in T cell differentiation as well as cytokine secretion. It was also reported that Lck mediates Th2 differentiation. The chronic inflammatory disease of the bronchial airways (asthma) was associated with activation of a Th2 type of T cell in the airway,. A study by Pernis et al. found that mice overexpressing or lacking Lck gene showed altered lung function suggesting their involvement in pathogenesis of asthma. Histological assessment of mice lung tissues by Zhang et al. revealed that Lck specific siRNA attenuated the pulmonary inflammation in asthma mice proposing Lck as a potential therapeutic target for asthma. Accordingly, since Lck was proved to be involved in the pathogenesis of asthma, a novel therapy for treatment of asthma can be developed based on Lck novel specific inhibitors.

Different studies reported the relation between Lck and other diseases rather than cancer and inflammation; the expression of Lck with Type I diabetes suggesting Lck as one of the main targets for diabetes treatment. A recent study reviewed the interplay of protein tyrosine phosphatases with Src kinases including Lck establishing their role in auto-immune mediated diabetes. The concept of Lck inhibition for the management of Type 1 diabetes was supported by another report suggested that βig-h3 represses T cell activation in Type 1 diabetes via inhibition of Lck. Moreover, blocking of Lck may provide a novel therapeutic target to manage atherosclerosis. A recent study showed T-cells in atherosclerosis patients to be cytotoxic towards vascular smooth muscle cells as well as endothelial cells, leading to vascular injury and plaque destabilisation. Lck might inhibit heat shock protein 65–mediated Reverse Cholesterol Transport in T cells which has been well established as one of the causes involved for atherosclerosis. Lck was also reported as a potential therapeutic target for acute rejection after kidney transplantation. Organ graft rejection occurs when the tissue transplanted in the recipient’s body is rejected by his immune system. Thus, inhibition of Lck has been established as a potential target to prevent organ graft rejection,.

Early discovery of Lck kinase inhibitors (selected examples)

By the year 2010, a large number of small molecules incorporating various chemical scaffolds were already reported to inhibit Lck,. In this section, we demonstrate some examples of the most promising candidates; the earliest members of this family are the ones possessing the pyrazolopyrimidine chemical scaffold; PP1 (I) and PP2 (II) (Figure 3), reported by Pfizer in 1996. Despite the low nanomolar Lck IC50 range of these two compounds (0.005 and 0.004 µM for PP1 and PP2, respectively), they showed lack of selectivity within Src kinase family. Further extended studies offered a direct descendant of PP1 (A-770041, III, Figure 3) which demonstrated a specific inhibition over Lck with an IC50 value of 0.147 µM. The final structure of this molecule is a result of both strategic modification and extensive SAR exploration aiming to improve the activity towards Lck and reduce activity against other members of the Src family while offering compounds with suitable pharmacokinetic properties,,.

Figure 3.

Chemical structures of compounds I–IV.

For different reasons such as the discovery of a chemical space available in the hydrophobic pocket and the solvent exposed binding region of Lck,, the difficulty of generating N7 variants of A-770041, and the hope to discover a highly selective Lck inhibitor via making productive contacts with the side chains of Tyr318 and the unique Glu320 in the extended hinge region of Lck, the pyrazolopyrimidine core was replaced with a thienopyridine scaffold offering compound IV with Lck IC50 value of 0.21 µM (Figure 3). The further SAR exploration confirmed that specificity could be generated through interactions with the hinge region. Analysis of compound IV against a larger kinase set showed improved selectivity within the Src family with significant decreases in activity against Src and Fyn relative to A-770041 (III). However, upon administration to mice, compound IV inhibited TCR stimulated IL-2 production with an ED50 of 5 mg/kg; the pharmacokinetic analysis demonstrated poor performance regarding clearance and oral bioavailability.

The benzothiazole compound BMS-243117 (V, Figure 4) was then reported following SAR exploration of a thiazole compound initially obtained via high throughput screening. Although compound V demonstrated a highly potent nanomolar activity over Lck (IC50 = 4 nM) and a promising inhibitory activity over T Cell proliferation with an IC50 value of 1.1 µM, it showed high inhibitory activity against other isoforms of Src family (Src IC50 = 632 nM, Fyn IC50 = 128 nM, Hck IC50 = 3.84 µM, Blk IC50 = 336 nM, Lyn IC50 = 1.32 µM, and Fgr IC50 = 240 nM), in addition, no in vivo data is reported for this promising candidate to date. Another aminoquinazoline-based highly potent Lck inhibitor (VI, Figure 4), possessing IC50 of 0.2 nM was identified via a high-throughput screening (HTS). Extended SAR studies of compound VI offered a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Orally bioavailable optimised analogs of compound VI exhibited a promising anti-inflammatory activity over the anti-CD3-induced production of interleukin-2 (IL-2) in mice. Although the selectivity of compound VI within the Src family was not studied during these initial SAR studies, some analogs showed potent nanomolar activity against other Src family isoforms. Screening of some pyrimidopyridazine-based small molecules against Lck led to the discovery of a novel 1,2-dihyrdropyrimido[4,5-c]pyridazine derivative (VII, Figure 4) with low micromolar activity towards Lck. Optimisation of this compound revealed the most promising analog of this series (VIII, Figure 4) which demonstrated good solubility and activity towards Lck (IC50 = 2 nM), although still with strong activity towards Src (IC50 = 3 nM).

Figure 4.

Chemical structures of compounds V–VIII.

A novel 4-amino-5,6-biaryl-furo[2,3-d]pyrimidine lead (IX, Figure 5) was discovered by DiMauro et al. as potent, non-selective inhibitor of Lck (IC50 = 0.081 µM) via HTS. The study further offered novel and expeditious synthetic route allowed for rapid diversification of the core scaffold and identification of compounds (X and XI, Figure 5) possessing higher potency over Lck with IC50 values of 0.009 and 0.036 µM, respectively. However, lack of selectivity was found; X and XI showed Src IC50 values of 0.045 and 0.914 µM, and Ack1 IC50 values of 0.098 and 0.078 µM, respectively. Further exploration of new 2,3-diarylfuro[2,3-b]pyridin-4-amines by Martin et al. offered some derivatives with promising potency but the lack of selectivity and the non-optimal pharmacokinetic properties limited the research efforts in this area. Martin et al. reported another series of 2-aminopyrimidine carbamates as a new class of compounds with potent and selective inhibition of Lck. The most promising compound of this series (XII, Figure 5) exhibits good activity when evaluated in an in vivo model of T cell activation. It showed an IC50 value of 0.0006 µM over Lck with an interesting selectivity profile (Src IC50 = 0.001 µM, Kdr IC50 = 0.14 µM, Syk IC50 = 0.20 µM, Zap-70 IC50 = 0.37 µM, and Btk IC50 = 0.10 µM).

Figure 5.

Chemical structures of compounds IX–XII.

New horizons in drug discovery of Lck inhibitors (2011–2020)

In the last decade, novel small molecules related to new chemical scaffolds were reported to inhibit Lck offering new horizons of drug discovery in this research area. By searching literature and pharmaceutical patents, we amass these efforts in this section. In addition, SAR studies and docking models of the most promising inhibitors within Lck active site were carried out to offer deep insights of their different binding modes in a step towards development of more potent, selective and safe Lck inhibitors as promising therapy for Lck-related human diseases.

The molecular docking study of the following discussed Lck inhibitors was performed in an attempt to assist in defining and categorising the functional groups of each series (which are involved in the ligand binding and which are not detrimental in binding). Classifying these groups will determine which must be excised and which should be preserved or modified, which in turn will pave the way for the development of more potent and selective inhibitors. Guided by co-crystal structures of different ligands to their corresponding Lck domains, the key interactions in ATP pocket are determined as follow: (1) The native ligands anchored in the hinge binding adenine pocket by hydrogen bond interactions with either the NH or the carbonyl groups of the main chain of Met319 amino acid; however, some co-crystal structures showed additional hydrogen bond interaction in the adenine region with the carbonyl oxygen of Glu317 backbone, (2) The hydrophobic pocket of Lck is occupied by the ligand via Van der Waals interaction with Asp382 residue, (3) Amongst the employed crystal structures, staurosporine-Lck complex revealed deep embedding of the methylamino nitrogen of the glycoside ring in ATP ribose pocket via participation in hydrogen bond interaction with Ser323 residue, 4) Finally, the ligand is positioned in Lck gatekeeper residue via hydrogen acceptor bond with the γ–OH of Thr316 residue,.

The molecular docking studies was performed using Molecular Operating Environment (MOE, 2014). The X-ray crystal structures of Lck domain were downloaded from the Protein Data Bank (PDB IDs: 1QPC, 1QPJ, 2OF2, 2OFU, 2PL0, 3BYM, 3BYO, 3LCK, and 6PDJ). Amino acid sequences of all protein were protonated and their energies were minimised. The employed crystal structures were docked with their native ligands, and their RMSD values were calculated. Only four PDB IDs: 2PL0, 3BYM, 3BYO, and 6PDJ of the lowest RMSD values were selected for operating docking protocol to the discussed inhibitors 1–38 (Figures 6(A), 7(A), 8, 10, 12, 14(A), 15) aiming at evaluation of their binding scores, and determination of their crucial binding interactions within Lck active site, comparable to the native ligand of the corresponding PDB file (Table 1). As depicted in Table 1, most of the docked compounds preserved the key interaction in the hinge binding site by hydrogen bond formation with Met319; while, the hydrophobic pocket was occupied by some compounds via Van der Waals interaction with Asp382; however, the gatekeeper Thr316 H-bonded with majority of the compounds, that in turn hypothesised their selectivity to Lck kinase among Src-family kinases. The correlation between the docking findings and the variable inhibitory activities is discussed in more details for each class.

Table 1.

Molecular docking study of compounds 1–38 in Lck kinase domain represented in 2D diagrams.

Cpd. ID	PDB ID	Energy Score(Kcal/mol)	2D diagram	Amino acids	Binding group	Molecular interactions
(Native ligand95)6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5′,4′:5,6] pyrimido-[1,2-a]benzimidazol-5(6H)-one	3BYO	−8.29		Met319	Pyrimidine (N)-NH	H-bond
				Val259	Imidazole ring	Arene-H
1	3BYO	−5.57		Met319	Phenoxy (Br)	H-bond
				Thr316	COOH (C = O)	H-bond
2	3BYO	−5.69		Met319	Phenoxy (I)	H-bond
				Thr316	COOH (C = O)	H-bond
3	3BYO	−5.75		Met319	Phenoxy (Br)	H-bond
(Native ligand97)Imatinib	2PL0	−10.66		Asp382	Amide-C = O	H-bond
				Glu288	Amide-NH	H-bond
				Ile361	Piperazine-NH	H-bond
				Met292	Amide-NH	H-bond
				Phe383	Pyrimidine ring	Ar-Ar
4	2PL0	−8.36		Ala381	Amide-C = O	H-bond
				Asp382	Amide-C = O	H-bond
				Met292	Amide-NH	H-bond
				Phe383	Pyrimidine ring	Ar-Ar
(Native ligand95)N-phenyl-1-(4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-amine	3BYM	−8.55		Asp382	Phenyl ring	Arene-H
				Glu317	Triazine-CH	H-bond
				Met319	Triazine (N)-NH	H-bond
				Val259	benzo[d]imidazole	Arene-H
5	3BYM	−6.63		Asp382	Phenoxy ring	Arene-H
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
				Met319	NH2	H-bond
6	3BYM	−5.98		Asp382	Pyrimidine ring	Arene-H
				Thr316	Pyrrole ring	Arene-H
7	3BYM	−6.57		Lys273	4-Br Phenoxy ring	Arene-H
				Met292	4-Br Phenoxy (Br)	H-bond
				Met319	NH2	H-bond
8	3BYM	−6.46		Asp382	4-Cl Phenoxy (Cl)	H-bond
				Leu251	Phenyl ring	Arene-H
9	3BYM	−6.66		Leu371	Phenyl ring	Arene-H
				Thr316	Phenoxy ring	Arene-H
10	3BYM	−7.54		Asp382	NH2	H-bond
				Met319	SO2	H-bond
				Tyr318	SO2	H-bond
11	3BYM	−6.89		Leu371	Phenyl ring	Arene-H
				Thr316	Phenoxy ring	Arene-H
12	3BYM	−6.66		Glu320	Piperidine (NH)	H-bond
				Gly322	Pyrrole ring	Arene-H
				Thr316	Phenoxy ring	Arene-H
13	3BYM	−7.71		Asp382	Phenyl ring	Arene-H
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
14	3BYM	−5.69		Asp382	Pyrimidine ring	Arene-H
				Thr316	Pyrrole ring	Arene-H
				Val301	Pyrimidine (N)	H-bond
15	3BYM	−6.38		Leu251	Benzyl group	Arene-H
				Thr316	Pyrimidine ring	Arene-H
				Val259	Pyrrole	Arene-H
16	3BYM	−6.64		Asp382	Phenyl ring	Arene-H
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
				Met319	NH2	H-bond
17	3BYM	−6.44		Asp382	Phenoxy ring	Arene-H
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
				Met319	NH2	H-bond
18	3BYM	−6.97		Gly322	Pyrrole ring	Arene-H
				Ser323	Pyrimidine ring	Arene-H
				Thr316	Phenoxy ring	Arene-H
19	3BYM	−6.61		Asp382	Phenoxy ring	Arene-H
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
				Met319	NH2	H-bond
20	3BYM	−6.62		Asp382	3-CN phenoxy (CN)	H-bond
				Leu251	Pyrrolo pyrimidine	Arene-H
				Thr316	Phenyl ring	Arene-H
21	3BYM	−6.50		Asp382	Amide-(C = O)	H-bond
				Met319	NH2	H-bond
				Val301	Amide-(NH2)	H-bond
22	3BYM	−6.70		Asp382	Phenyl ring	Arene-H
				Leu251	Pyrrolo pyrimidine	Arene-H
				Met319	NH2	H-bond
23	3BYM	−6.81		Leu251	Phenoxy ring	Arene-H
				Lys269	4-CF3 phenyl group	Arene-H
				Thr316	Furan (O)	H-bond
				Val259	Pyrimidine ring	Arene-H
24	3BYM	−5.86		Leu251	Thiophene ring	Arene-H
				Met319	Triazole (N)	H-bond
				Thr316	2-Cl,6-F-phenyl group	Arene-H
25	3BYM	−6.17		Met319	Triazole (N)	H-bond
				Thr316	2-Cl,6-F-phenyl group	Arene-H
26	3BYM	−6.57		Asp382	2-Cl,6-F-phenyl group	Arene-H
27	3BYM	−6.87		Glu317	Triazole (NH)	H-bond
				Leu251	3-NH2, 4-OMe phenyl group	Arene-H
				Met319	Triazole (N)	H-bond
28	3BYM	−6.34		Met319	Triazole (N)	H-bond
29	3BYM	−6.16		Met319	Triazole (N)	H-bond
				Thr316	2-Cl,6-F-phenyl group	Arene-H
30	3BYM	−7.00		Leu251	Thiazole ring	Arene-H
				Met319	Thiazole (S)	H-bond
					NH	H-bond
31	3BYM	−7.63		Asp382	Pyridine ring	Arene-H
				Glu249	Piperazine (NH)	Metal/Ione
				Gly322	Pyrimidine ring	Arene-H
				Leu251	Pyrimidine ring	Arene-H
				Leu371	Thiazole ring	Arene-H
				Met319	Thiazole (N)	H-bond
					NH	H-bond
32	3BYM	−6.98		Met319	NH2	H-bond
				Val259	Naphthyl group	Arene-H
(Native ligand98)N-(4-(6-methoxypyrazolo[1,5-a]pyridine-3-carboxamido)-3-methylphenyl)-1-methyl-1H-indazole-3-carboxamide (37)	6PDJ	−11.39		Asp382	Amide-C = O	H-bond
				Met319	Pyrazole (N)	H-bond
				Phe283	Pyrazole ring	Arene-H
33	6PDJ	−7.59		Met319	Pyrimidine (N)	H-bond
				Tyr318	CH	Arene-H
34	6PDJ	−7.95		Met319	Pyrimidine (N)	H-bond
35	6PDJ	−7.17		Met319	Pyrimidine (N)	H-bond
36	6PDJ	−6.52		Ala284	Amide (NH)	H-bond
				Asp382	Azetidine (CH)	Arene-H
				Met292	Urea (NH)	H-bond
				Phe285	Indazole (Pyrazole ring)	Arene-H
				Phe256	3-Cl phenyl group	Arene-H
38	6PDJ	−9.50		Ala289	CN group	H-bond
				Asp382	Amide (NH)	H-bond
				Met292	Indazole (Pyrazole ring)	H-bond
				Phe383	Amide (NH)	Arene-H

Halogenated alkaloids

HPLC-ESIMS (High-performance liquid chromatography combined with electrospray mass spectrometry) guiding fractionation of the sponge I. purpurea resulted in the isolation of ten polyhalogenated alkaloids (Purpuroine A–J). The newly isolated purpuroines were assayed for their antibiotic and kinase inhibition activities. Although the initial assays were limited to a small panel of three different kinases including Lck, cyclin-dependent kinase 2 (CDK2), and polo-like kinase 1 (PLK1), purpuroines A (1) and D (2) (Figure 5(A)) showed potent inhibitory activity against Lck kinase with IC50 values of 2.35 and 0.94 µg/mL, respectively. Purpuroine D was also found to inhibit PLK1 with an IC50 value of 1.45 µg/mL. As a reference, staurosporine (a broad-spectrum protein kinase inhibitor) exhibited IC50 values of 3.73 and 0.92 µg/mL over Lck and PLK1, respectively. All purpuroines displayed weak inhibition to CDK2 (IC50 > 50 µg/mL). The primary SAR analysis of the trihalogen substituted analogs including the most potent compound (purpuroine D) presented their ability to show more inhibitory activity against Lck than the dihalogentaed analogs as in purpuroine B (3, Figure 6(A)). A molecular docking simulation was performed to get more insights about the different binding modes of this series within the Lck active site and to understand the possible reason(s) behind the difference in their biological activities. The docking study indicated that compounds 1 (Figure 6(B)) and 2 possessing tri-halogenated phenoxy group were deeply embedded in the hinge binding region via formation of H-bond with Met319 residue, leading to orientation of molecule’s lateral carboxylic acid group towards H-bonding with Thr316. On the other hand, the di-halogenated phenoxy in compound 3 (Figure 6(C)) is H-bonded through the bromo group with Met319, even though, the molecule didn’t show any additional H-bonds with amino acid residues in the adenine binding area.

Figure 6.

(A) Chemical structures of halogenated alkaloids 1–3; (B) 3D molecular interaction docking model of compound 1 in Lck kinase domain active site (PDB ID: 3BYO) (C) 3D molecular interaction docking model of compound 3 in Lck kinase domain active site (PDB ID: 3BYO).

8-Methyl-1-phenyl-imidazo[l,5-a]pyrazines

Using Lck IMAP assay, design of a new series of 8-methyl-1-phenyl-imidazo[l,5-a]pyrazines as Lck inhibitors resulted in the discovery of novel Lck inhibitory derivatives with a wide range of pIC50 values against Lck (≥6 – ≥8). Compound 4 (Figure 7(A)) is reported as one among many derivatives exhibited a potent inhibitory activity over Lck with pIC50 value ≥8. Docking of compound 4 (Figure 7(B)) in the active site of Lck (PDB ID: 2PL0) illustrated a similar binding behaviour of imatinib (selective inhibitor of Lck among Src-family kinases); the amide linker of compound 4 conserved the essential hinge binding interactions with the back bone of Met292 and Glu288 amino acids via H-bond formation with NH, while the carbonyl part H-bonds with the NH of both Ala381and Asp381 residues. Moreover, the imidazopyrimidine moiety occupied the hydrophobic pocket and involved in Van der Waals interactions with Phe383.

Figure 7.

(A) Chemical strucutre of compound 4; (B) 3D molecular interaction docking model of compound 4 in Lck kinase domain active site (PDB ID: 2PL0).

Pyrrolopyrimidines

Novel pyrrolopyrimidine-based Lck inhibitors were patented by Laurent et al. from the Canadian pharmaceutical company Pharmascience Inc. At the molecular level, the kinase inhibitory activity (expressed as K values) of the newly synthesised compounds was assessed against Lck and Bruton’s tyrosine kinase (Btk). Using splenic cell proliferation assay, EC50 values (50% proliferation in the presence of compound as compared to vehicle treated controls) were also determined at the cellular level. As illustrated in Figure 8, nineteen compounds belonging to five different general structures were selected to elucidate the SAR of this new series (Table 2).

Figure 8.

Chemical structures of pyrrolopyrimidine-based Lck inhibitors 5–23.

Table 2.

Biological activity of compounds 5–23 over Lck.

Cpd	Ki Lck (nM)
5, 14, 15, 16, 17, 18, 19, 22, and 23	<100
7, 8, 9, 10, 11, 12, and 13	>100 – <1000
6, 20, and 21	>1000

It was noted that compounds 5–8 possessing cyclopentene ring exhibited a wide range of Lck inhibition; while compound 5 possessing unsubstituted phenoxy moiety exhibited a potent inhibition constant (K value < 100 nM), compounds 7 and 8 with bromo and chloro substituted phenoxy, respectively, exhibited higher K values (> 100 – < 1000 nM). A total loss of the nanomolar activity was found in case of compound 6 possessing p-fluorophenoxy moiety (K value > 1000 nM). Alteration of the cyclopentene ring into the 5-membered (un)substituted 2,5-dihydro-1H-pyrrole (9 and 10) and ring expansion into the 6-membered cyclohexene (11) and 1,2,3,6-tetrahydropyridine (12) retrieved the modest activity (K value > 100 – < 1000 nM). While substitution of the free NH in 1,2,3,6-tetrahydropyridine ring with benzenesulphonyl moiety (13) did not improve this modest activity, substitution with a small size ethyl group (14) greatly increased the inhibitory activity against Lck (Ki value < 100 nM). Retrieving the 5-membered cyclopentene moiety along with replacement of the phenoxy moiety with benzyl resulted in compound 15 which also demonstrated a potent Lck inhibition (K value < 100 nM). Although an introduction of the isostere 5-membered 2,5-dihydrofuran (16) or 2-methyl-2,5-dihydrofuran (17–19) instead of the cyclopentene ring, along with keeping the phenoxy moiety, maintained the high potency, substitution of the phenoxy moiety in the meta position with cyano (20) or carboxamide group (21) resulted in loss of the nanomolar activity. Interestingly, the high potency was retrieved when the phenoxy moiety was substituted in the meta position with pyridin-3-ylmethoxy group (22) and 4-(trifluoromethyl)benzyloxy group (23). Molecular modelling studies in the active site of Lck (PDB ID: 3BYM) were carried out to understand the superiority in activity of the 5-membered rings (cyclopentene, 2,5-dihydrofuran, and 2-methyl-2,5-dihydrofuran ring) over the 6-membered ring 1,2,3,6-tetrahydropyridine, in addition, to figure out the role of the meta position substitution of the phenoxy moiety in the biological activity over Lck.

As demonstrated in Table 1, the docked derivatives exhibited variable interaction modes; however, the most potent inhibitors exhibited the highest affinity to the enzyme active site. For instance, compound 5 (Figure 9(A)) embedded deeply via multiple interactions within the pocket residues. Compound 5 anchored to the adenine area by H-bond with Met319 residue, also, the un-substitution on the phenoxy moiety allowed its deep interaction into the hydrophobic pocket via Arene-H bond with Asp382 back chain, while, the pyrrolopyrimidine scaffold contributed in holding the compound in this position by hydrophobic interaction with Gly322 and Leu251 amino acid residues. In contrary, p-fluoro substitution on the phenoxy group in compound 6 (Figure 9(B)) flipped the compound in the active site and resulted in moving the amino group away from the hinge binder which is supposed to badly affect the compound stability in the enzyme active site and reduce its activity. However, the observed moderate activity upon replacement of the cyclopentene ring into substituted 2,5-dihydro-1H-pyrrole in compound 10 (Figure 9(C)) could be explained due to the contribution of the substituted sulphonyl (SO2) group in two H-bonds with Met319 in the hinge binder and Thr316 in the hydrophobic pocket.

Figure 9.

3D molecular interaction docking models of compound 5 (A), compound 6 (B), and compound 10 (C) in Lck kinase domain active site (PDB ID: 3BYM).

Substituted triazoles

A series of substituted triazole-based compounds were designed and synthesised as new kinase inhibitors from the national institute of biological sciences in Beijing,. Upon screening of forty-two compounds over a panel of seven autoimmune disease-related kinases including Lck, Btk, P38a, Fyn, Lyn, BMX, and Blk, only two compounds (24 and 25, Figure 10) exhibited highly potent and selective activities over Lck with IC50 values less than 0.1 µM.

Figure 10.

Chemical structures of triazole-based compounds 24–29.

While most of other compounds exhibited moderate activities against Lck with an IC50 range of 0.1–10 µM, it was noted that only compound 26 (Figure 10) was totally inactive over Lck (IC50 > 10 µM). It was also found that compounds 27, 28, and 29 (Figure 10) belonging to the same series were able to inhibit Lck in a high nanomolar IC50 range (0.077 ± 0.022, 0.018 ± 0.007, and 0.044 ± 0.02, respectively) despite their high activity against other kinases. A molecular docking study of this groupoffered insights into their different binding modes in the active site of Lck and proposed an explanation for their variable activities. The highly potent derivatives 24 (Figure 11(A)) and 25 were able to fit into the active site, where the triazole nitrogen atom is conserving H-bonding interaction with Met319 amino acid backbone in the hinge binding region, while, the lateral substituted benzylamine moiety was oriented towards the gatekeeper pocket through Arene-H interaction with Thr316 residue. The conformation of the moderately active non selective inhibitors 27–29 preserved the central triazole ring held in the adenine binding region, but hindered the benzyl moiety interaction in the hydrophobic pocket (Figure 11(C)). Compound 26 did not exhibit the fundamental binding interactions in the hinge region (Figure 11(B)).

Figure 11.

3D molecular interaction docking models of compound 24 (A), compound 26 (B), and compound 27 (C) in Lck kinase domain active site (PDB ID: 3BYM).

Dasatinib-derived Lck inhibitor

Dasatinib (30, Figure 12) is one of the tyrosine kinase inhibitors (TKIs) which has transformed the treatment of Chronic Myeloid Leukaemia (CML), with chronic-phase CML now considered a manageable chronic disease. It is an orally administered small molecule inhibitor of many tyrosine kinases at nanomolar concentrations, including BCR-ABL1, c-Kit, EphA2, platelet-derived growth factor receptor-b and the Src family of kinases (e.g. Src, Lck, Yes, Fyn). However, dasatinib which is metabolised in humans primarily by the cytochrome P450 enzyme 3A4 (CYP3A4) is also a time-dependent inhibitor of CYP3A4, accordingly, the dosage of dasatinib must be significantly decreased if the patient is concomitantly medicated with a strong CYP3A4 inhibitor such as ketoconazole, clarithromycin, and indinavir, since these drugs may increase the plasma concentration of dasatinib to unsafe levels. The administration of dasatinib should be stopped upon occurrence of myelosuppression. In addition, dasatinib causes inhibition of hERG (the human “Ether-a-go-go-Related Gene”) which is an ion channel involved in the electrical activity of the heart and the coordination of heart beating.Dasatinib also suffers from an extremely short half-life, with an overall mean terminal half-life of only 3–5 h. Accordingly, in a recent trial to develop a dasatinib-derived new inhibitor with better pharmacological and safety profile, compound 31 (Figure 12) was reported by Sennthenn et al. and found to inhibit multiple kinases including Lck with an IC50 value of 1.5 nM.

Figure 12.

Chemical structure of Dasatinib (30) and its derivative 31.

Docking the structurally modified derivative 31 (Figure 13(B)) revealed significant changes in the compound conformation in the active site of Lck (PDB ID: 3BYM), compared to the lead compound (dasatinib, Figure 13(A)) . While the main hinge binder interaction with Met319 via the 2-aminothiazole central scaffold was conserved in the modified compound, such a small change in the terminal aromatic amide in dasatinib by the pyridinyl amide in compound 31 oriented the compound to bind deeply in the hydrophobic pocket via Arene-H interaction with Asp382. Additional molecular interactions were observed as a result of these conformational changes, the pyrimidine ring contributed by a pair of Arene-H interactions with Gly322 and Leu 251 amino acids. Also, the nitrogen atom of the lateral piperazine participated in Metal/Ione interaction with Glu249.

Figure 13.

3D molecular interaction docking models of dasatinib (30) (A) and compound 31 (B) in Lck kinase domain active site (PDB ID: 3BYM).

Prodan-derived Lck inhibitor

In an attempt to find a prodan-derived Lck inhibitor which could serve as a molecular tool for real-time intracellular studies of Lck signalling, a small ATP-competitive Lck inhibitor (32, IC50 = 124 nM, Figure 14(A)) with innate fluorescent properties has been discovered by Fleming et al. through the integration of a prodan-derived fluorophore into the pharmacophore of the kinase inhibitor. Docking of compound 32 in the Lck active site (PDB ID: 3BYM, Figure 14(B)) revealed the pyrazolopyrimidine main scaffold to be buried in the adenine binding site by H-bonding between the amino group in the compound and Met319 backbone. While, the hydrophobic pocket was occupied by the naphthyl moiety which participated in Arene-H interaction with Val259.

Figure 14.

(A) Chemical structure of compound 32; (B) 3D molecular interaction docking model of compound 32 in Lck kinase domain active site (PDB ID: 3BYM).

Phenoxypyrimidines

A novel series of phenoxypyrimidine scaffold-based inhibitors was recently reported from Korea Institute of Science and Technology (KIST) targeting Lck and FMS kinases for inflammatory disorders. While this study concluded the discovery of a new Lck/FMS dual inhibitor (33, Figure 15) with highly potent nanomolar IC50 values of 22.0 ± 10.0 and 4.6 ± 0.05 nM against Lck and FMS kinases, respectively, in addition to its ability to demonstrate a promising anti-inflammatory effect, compounds 34 and 35 (Figure 15) with Lck IC50 value of 0.0065 ± 0.002 and 0.006 ± 0.0005 µM, respectively, were found to be the most potent Lck inhibitors in this series.

Figure 15.

Chemical structures of phenoxypyrimidine scaffold-based Lck inhibitors 33–35.

Molecular docking of the synthesised phenoxypyrimidine derivatives 33–35 in the Lck active site (PDB ID: 6PDJ, Figure 16), revealed the fundamental role of 2-aminopyrimidine core in stabilising the inhibitors in the active site of the enzyme. The nitrogen atom of the pyrimidine acted as a H-bond acceptor and kept the molecules in the hinge binding region by forming a H-bond interaction with Met319. Furthermore, the substituted phenoxy moiety was oriented towards the hydrophobic pocket, even though it didn’t show remarkable interactions with the amino acid residues in this area.

Figure 16.

3D molecular interaction diagrams of compound 33 (A), compound 34 (B), and compound 35 (C) in Lck kinase domain active site (PDB ID: 6PDJ).

Pyrazolo[1,5-a]pyridines

Bristol-Myers Squibb screened an internal kinase inhibitor collection which led to identify a pyridazinone lead compound (36, Figure 17) as a starting point for development of novel inhibitors of C-terminal Src Kinase to evaluate the potential of this target for an immuno-oncology therapy. Upon a series of modifications included switching from a pyridazinone to pyrazolopyridine hinge binder, the optimised analog 37 (Figure 17) showed a promising ability to increase T cell proliferation induced by T cell receptor signalling and an excellent potential to reduce Lck phosphorylation in vivo upon oral dosing with Lck IC50 = 260 nM. The most potent compound in this series over Lck was compound 38 (Figure 17, IC50 = 26 nM) which showed 10-folds of potency compared to compound 37.

Figure 17.

Chemical structures of pyrazolo[1,5-a]pyridine-based Lck inhibitors 36–38.

The molecular interactions of the developed inhibitors were elaborated by their docking in the Lck active site (PDB ID: 6PDJ). As illustrated in Figure 18, the native ligand (37) showed fit binding in the enzyme pocket; where the pyrazolo[1,5-a]pyridine’s N1 formed a H-bond with Met319 in the hinge binding area, while, the hydrophobic pocket was occupied by the lateral indazole-3-carboxamide moiety via H-bonding with Asp382 and Arene-H interaction with Phe383. On the other hand, the pyridazinone moiety of the initial identified lead 36 was positioned away from the hinge region with no observed interactions. In addition, the indazole-3-carboxamide moiety was anchored in the hydrophobic pocket through H-bonding with Met292, and a couple of Arene-H interactions between the azetidine ring and the indazole moiety with Asp382 and Phe285, respectively. The modified potent inhibitor 38 showed the highest affinity to the binding site; the pyrazolo[1,5-a]pyridine carboxamide moiety was positioned to the hinge region, while, the indazole-3-carboxamide moiety was bound in the hydrophobic pocket where the carboxamide-NH group H-bound with both Met292 and Asp382. Also, the indazole moiety formed an Arene-H interaction with Phe285. Moreover, the long chain substitution on the indazole N1 of 38 allowed the compound to extend deeply in the pocket via formation of a H-bond between the terminal CN group and Ala289 residue.

Figure 18.

3D molecular interaction diagrams of compound 36 (A), compound 37 (B), and compound 38 (C) in Lck kinase domain active site (PDB ID: 6PDJ).

Conclusion

Fuelled by the recent development of kinase inhibitor small molecules as an area of intense research, Lck is well established as a promising target for the next generation of kinase inhibitors. However, due to the high homology of Lck with other members of the Src family isoforms, complications in the development of Lck inhibitors are still found. There is no doubt that off target inhibition of other Src family members has the potential to inhibit numerous essential cellular functions. Accordingly, the successful Lck inhibitory chemical scaffold must show high activity towards Lck, relatively little activity towards other Src kinases as well as a promising in vitro cell-based and in vivo data to support its further consideration as promising clinical candidate. Despite the extensive research efforts to optimise a promising Lck inhibitor possessing the above-mentioned criteria, the development of Lck specific inhibitors with good bioavailability and pharmacokinetics is still elusive. The efforts thrown in developing potent selective inhibitors are focussing on deep analysis of the targeted enzyme active site and defining its specific key interactions. Among Src kinases family, Lck has an advantage of sequence differences where Lck gatekeeper is characterised by hydrogen bonding between the γ OH of Thr316 and a H-bond acceptor group in the corresponding inhibitors. Considering this specific hydrogen bonding might help in designing Lck selective inhibitors by introducing well-positioned groups to accept H-bond from Thr316.

Molecular docking of the presented inhibitors showed variable interaction modes in Lck active site; however, following their reported SAR revealed that the key point for improving the activity is conserving the essential interactions in the Lck active site including H-bond interaction with Met319 in the hinge binder, Van der Waals interaction with Asp382 in the hydrophobic pocket, and binding to Lck gatekeeper with Thr316. Moreover, additional molecular interactions were detected by some inhibitors, which in turn boosted the inhibitors affinity and stability in Lck active site and explained their improved activity. In summary, deep understanding of the different structural interactions of inhibitor molecules with multiple closely related enzymes has the potential to provide data useful in the rational design of kinase inhibitors and the development of novel Lck inhibitors. Moreover, small‐molecule allosteric kinase inhibitors possessing the significant advantages over ATP‐competitive kinase inhibitors such as greater selectivity and lower off‐target toxicity could be the next generation of specific Lck inhibitors that can be optimised for clinical use. Thus, the efficient rational approaches for rapid discovery of new allosteric hits for Lck, as well as systematic biological assay technologies, are urgently needed.

CRediT authorship contribution statement

Ahmed Elkamhawy: Conceptualisation, Methodology, Writing-original draft, and Data curation.

Eslam M.H. Ali: Visualisation, Software, Writing-modelling section.

Kyeong Lee: Supervision, Funding acquisition, Review and editing.